The effect of vitamin D supplementation at diagnosis of pneumonia upon response to treatment
ISRCTN | ISRCTN61245920 |
---|---|
DOI | https://doi.org/10.1186/ISRCTN61245920 |
Secondary identifying numbers | N/A |
- Submission date
- 27/02/2007
- Registration date
- 21/03/2007
- Last edited
- 30/10/2008
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Respiratory
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Plain English summary of protocol
Not provided at time of registration
Contact information
Dr Semira Manaseki-Holland
Scientific
Scientific
Aga Khan Health Services Afghanistan
House No. 648, Street No. 9-B
Sherpoor, Shahr-e-Naw
District 10
Kabul
-
Afghanistan
Phone | +93 (0)79 941 0124 |
---|---|
semira.manasekiholland@akdn-afg.org |
Study information
Study design | Double blind randomised controlled trial |
---|---|
Primary study design | Interventional |
Secondary study design | Randomised controlled trial |
Study setting(s) | Not specified |
Study type | Not Specified |
Scientific title | |
Study objectives | There is no difference in the incidence of pneumonias or their severity for children diagnosed with pneumonia supplemented with 100,000 IU vitamin D at the start of the cold season and 3 months later compared to placebo. |
Ethics approval(s) | Institutional Review Board of the Ministry of Public Health of Afghanistan. Approved on 19 November 2006. Ref: 237783 |
Health condition(s) or problem(s) studied | Pneumonia |
Intervention | Vitamin D3 100,000 IU supplementation vs placebo |
Intervention type | Supplement |
Primary outcome measure | Duration of pneumonia as measured from the date of clinical diagnosis and treatment onset to the last date of illness with any of the following criteria: 1. Respiratory rate according to age and IMCI criteria 2. No danger signs or subcostal recession 3. No fever (temperature < 38.0 °C or < 37.50 °C if < 2 month old) |
Secondary outcome measures | 1. Incidence of further episodes within 3 months or relapse of pneumonia (The Integrated Management of Childhood Illness [IMCI] defined rapid breathing and cough) 2. Rate of failure to respond to treatment or worsening condition rate (as defined by protocol) |
Overall study start date | 09/12/2006 |
Completion date | 30/05/2007 |
Eligibility
Participant type(s) | Patient |
---|---|
Age group | Child |
Lower age limit | 1 Week |
Upper age limit | 18 Months |
Sex | Not Specified |
Target number of participants | 450 |
Key inclusion criteria | Any child, living in the defined areas of Kabul (within the catchment area of the Maywand Teaching Hospital), between 1 week and 18 complete months of age. |
Key exclusion criteria | 1. >8 hours after the start of hospital antibiotics treatment 2. Living outside of the study areas of Kabul and childs families expect to move away within the next 3 months 3. If the child has been diagnosed with clinical rickets or known to have received a course of high dose vitamin D treatment in the past 3 months (doses as high as 300,000 IU are used routinely in India and Pakistan, and thus rarely, some recently returned returnee children may have recently received such doses) 4. If have symptoms of very severe pneumonia (according to IMCI definitions of very severe pneumonia) or other illnesses as the major diagnosis occurring at the same time as pneumonia, such as meningitis, major heart or renal defect, active measles, severe malnutrition requiring separate medical treatment, and suspected tuberculosis 5. Child with severe diarrhoea or vomiting 6. Wheeze at the time of diagnosis (if wheeze develops later the child continues to be in the study) 7. Caretakers do not give consent |
Date of first enrolment | 09/12/2006 |
Date of final enrolment | 30/05/2007 |
Locations
Countries of recruitment
- Afghanistan
Study participating centre
Aga Khan Health Services Afghanistan
Kabul
-
Afghanistan
-
Afghanistan
Sponsor information
Aga Khan Health Services Afghanistan (Afghanistan)
Other
Other
House No. 648, Street No. 9-B
Sherpoor, Shahr-e-Naw
District 10
Kabul
-
Afghanistan
Phone | +93 (0)79 941 0124 |
---|---|
semira.manasekiholland@akdn-afg.org |
Funders
Funder type
Government
New Zealand Aid and International Development Agency (New Zealand)
No information available
In kind donations from Aga Khan Development Network and Maywand Teaching Hospital (funded by the Government of Afghanistan) (Afghanistan)
No information available
Results and Publications
Intention to publish date | |
---|---|
Individual participant data (IPD) Intention to share | No |
IPD sharing plan summary | Not provided at time of registration |
Publication and dissemination plan | Not provided at time of registration |
IPD sharing plan |
Study outputs
Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
---|---|---|---|---|---|
Results article | results | 01/01/2008 | Yes | No |